Share-Based Compensation (Details) [Line Items]

908,505

3,333

633,336

The original vesting period for these RSAs is as follows: 283,339 were to vest on the one-year anniversary of the grant date; 283,331 were to vest on the two-year anniversary of the original grant date; and 66,666 were scheduled to vest on the three-year anniversary of the original grant date. As of December 31, 2020, 283,339 RSAs had vested. In the first quarter of fiscal 2021, the Company modified the RSA awards for two individuals to accelerate the final vesting of their awards in consideration of the individuals’ separation and/or retirement. This modification resulted in the vesting of an additional 50,000 RSAs. An incremental compensation expense was recognized for the modification totaling $166,920 during the three months ended March 31, 2021. As of March 31, 2021, the remaining unvested RSAs from these awards, totaling 299,997, are scheduled to vest as follows: 233,331 are scheduled to vest on the two-year anniversary of the original grant date; and 66,666 were scheduled to vest on the three-year anniversary of the original grant date.

Vesting period, description

The vesting period for these RSAs is as follows: 33,334 vest on the one-year anniversary of the grant date and 33,333 vest on the two-year anniversary of the original grant date.

Recognized of compensation expense (in Dollars)

$ 349,080

Recognized of share-based compensation expense (in Dollars)

7,374

Aggregate of shares common stock

4,433,734

Estimated per share (in Dollars per share)

$ 1.918

$ 1.597

Warrants, description

the Company issued warrants to purchase an aggregate of 100,000 shares of the Company’s common stock as consideration for certain costs related to the First Offering as disclosed in Note 17 – Stockholders’ Equity. The Representative’s First Offering Warrants are subject to a lock-up for 180 days from the commencement of sales in the First Offering, including a mandatory lock-up period in accordance with FINRA Rule 5110(e), and will be non-exercisable for six (6) months after January 21, 2021. The warrants have an exercise price of $4.15 per share and an expiration date of January 21, 2026. The issuance date fair value of these warrants, using the Black-Scholes Option-Pricing model, was estimated to be $1.703 per share for a total of $170,300. None of these warrants were exercised during the three months ended March 31, 2021. On January 26, 2021, the Company issued warrants to purchase an aggregate of 154,216 shares of the Company’s common stock as the Representative’s First Offering Warrants as discussed in Note 17 – Stockholders’ Equity. The warrants have an exercise price of $5.1875 per share and an expiration date of January 21, 2026. The issuance date fair value of these warrants, using the Black-Scholes Option-Pricing model, was estimated to be $1.376 per share for a total of $212,201. None of these warrants were exercised during the three months ended March 31, 2021. On February 12, 2021, the Company issued warrants to purchase an aggregate of 225,882 shares of the Company’s common stock as the Representative’s Second Offering Warrants as discussed in Note 17 – Stockholders’ Equity. The Representative’s Second Offering Warrants are subject to a lock-up for 180 days from the commencement of sales in the Second Offering, including a mandatory lock-up period in accordance with FINRA Rule 5110(e), and will be non-exercisable for six (6) months after February 10, 2021. The warrants have an exercise price of $5.3125 per share and an expiration date of February 10, 2026. The issuance date fair value of these warrants, using the Black-Scholes Option-Pricing model, was estimated to be $1.918 per share for a total of $433,242.

Weighted average grant date fair value per share (in Dollars per share)

$ 1.60

Share-Based Compensation (Details) [Line Items]

Warrants price per share (in Dollars per share)

$ 4.50

Estimated fair value, total (in Dollars)

$ 4,394,235

Share-Based Compensation (Details) [Line Items]

Aggregate of restricted stock

66,667

Share-Based Compensation (Details) - USD ($)			1 Months Ended	3 Months Ended
Share-Based Compensation (Details) - USD ($)	Feb. 12, 2021	Dec. 02, 2019	Jan. 26, 2021	Mar. 31, 2021
Share-Based Compensation (Details) [Line Items]
Common stock authorized awards to granted				3,333,334
Number of shares issued				908,505
Number of shares forfeited				33,334
Exercised shares				3,333
Number of common shares authorized				2,458,163
Aggregate of restricted stock		633,336
Fair value of per share (in Dollars per share)		$ 2.46
Restricted stock units, description				The original vesting period for these RSAs is as follows: 283,339 were to vest on the one-year anniversary of the grant date; 283,331 were to vest on the two-year anniversary of the original grant date; and 66,666 were scheduled to vest on the three-year anniversary of the original grant date. As of December 31, 2020, 283,339 RSAs had vested. In the first quarter of fiscal 2021, the Company modified the RSA awards for two individuals to accelerate the final vesting of their awards in consideration of the individuals’ separation and/or retirement. This modification resulted in the vesting of an additional 50,000 RSAs. An incremental compensation expense was recognized for the modification totaling $166,920 during the three months ended March 31, 2021. As of March 31, 2021, the remaining unvested RSAs from these awards, totaling 299,997, are scheduled to vest as follows: 233,331 are scheduled to vest on the two-year anniversary of the original grant date; and 66,666 were scheduled to vest on the three-year anniversary of the original grant date.
Fair value of per share (in Dollars per share)			$ 4.50
Vesting period, description			The vesting period for these RSAs is as follows: 33,334 vest on the one-year anniversary of the grant date and 33,333 vest on the two-year anniversary of the original grant date.
Vested percentage				100.00%
Recognized of compensation expense (in Dollars)				$ 349,080
Unrecognized compensation cost (in Dollars)				821,706
Recognized of share-based compensation expense (in Dollars)				7,374
Unrecognized compensation expense (in Dollars)				$ 9,836
Aggregate of shares common stock			4,433,734
Warrants price per share (in Dollars per share)	$ 5.3125		$ 4.50
Estimated per share (in Dollars per share)	$ 1.918		$ 1.597
Estimated fair value, total (in Dollars)	$ 433,242
Warrants, description			the Company issued warrants to purchase an aggregate of 100,000 shares of the Company’s common stock as consideration for certain costs related to the First Offering as disclosed in Note 17 – Stockholders’ Equity. The Representative’s First Offering Warrants are subject to a lock-up for 180 days from the commencement of sales in the First Offering, including a mandatory lock-up period in accordance with FINRA Rule 5110(e), and will be non-exercisable for six (6) months after January 21, 2021. The warrants have an exercise price of $4.15 per share and an expiration date of January 21, 2026. The issuance date fair value of these warrants, using the Black-Scholes Option-Pricing model, was estimated to be $1.703 per share for a total of $170,300. None of these warrants were exercised during the three months ended March 31, 2021. On January 26, 2021, the Company issued warrants to purchase an aggregate of 154,216 shares of the Company’s common stock as the Representative’s First Offering Warrants as discussed in Note 17 – Stockholders’ Equity. The warrants have an exercise price of $5.1875 per share and an expiration date of January 21, 2026. The issuance date fair value of these warrants, using the Black-Scholes Option-Pricing model, was estimated to be $1.376 per share for a total of $212,201. None of these warrants were exercised during the three months ended March 31, 2021. On February 12, 2021, the Company issued warrants to purchase an aggregate of 225,882 shares of the Company’s common stock as the Representative’s Second Offering Warrants as discussed in Note 17 – Stockholders’ Equity. The Representative’s Second Offering Warrants are subject to a lock-up for 180 days from the commencement of sales in the Second Offering, including a mandatory lock-up period in accordance with FINRA Rule 5110(e), and will be non-exercisable for six (6) months after February 10, 2021. The warrants have an exercise price of $5.3125 per share and an expiration date of February 10, 2026. The issuance date fair value of these warrants, using the Black-Scholes Option-Pricing model, was estimated to be $1.918 per share for a total of $433,242.
Aggregate of purchase shares	225,882
Weighted average grant date fair value per share (in Dollars per share)	$ 1.60
Warrant [Member]
Share-Based Compensation (Details) [Line Items]
Aggregate of shares common stock			2,751,556
Warrants price per share (in Dollars per share)			$ 4.50
Estimated per share (in Dollars per share)			$ 1.597
Estimated fair value, total (in Dollars)			$ 4,394,235
Black-Scholes Option-Pricing model [Member]
Share-Based Compensation (Details) [Line Items]
Warrants, description			the Company issued warrants to purchase an aggregate of 154,216 shares of the Company’s common stock as the Representative’s First Offering Warrants as discussed in Note 17 – Stockholders’ Equity. The warrants have an exercise price of $5.1875 per share and an expiration date of January 21, 2026. The issuance date fair value of these warrants, using the Black-Scholes Option-Pricing model, was estimated to be $1.376 per share for a total of $212,201.
Board of Directors [Member]
Share-Based Compensation (Details) [Line Items]
Aggregate of restricted stock			66,667